Sonoma Pharmaceuticals, Inc. (SNOA): Price and Financial Metrics

Sonoma Pharmaceuticals, Inc. (SNOA): $0.77

0.01 (-1.04%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add SNOA to Watchlist
Sign Up

SNOA Price/Volume Stats

Current price $0.77 52-week high $3.34
Prev. close $0.78 52-week low $0.72
Day low $0.72 Volume 74,400
Day high $0.78 Avg. volume 855,587
50-day MA $0.94 Dividend yield N/A
200-day MA $1.10 Market Cap 3.97M

SNOA Stock Price Chart Interactive Chart >

SNOA Stock Summary

  • SONOMA PHARMACEUTICALS INC's market capitalization of $4,011,360 is ahead of merely 2.2% of US-listed equities.
  • With a year-over-year growth in debt of -31.2%, SONOMA PHARMACEUTICALS INC's debt growth rate surpasses just 10.31% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SNOA comes in at -67.41% -- higher than that of just 8.47% of stocks in our set.
  • Stocks that are quantitatively similar to SNOA, based on their financial statements, market capitalization, and price volatility, are ADSE, SPWR, TREE, RMTI, and EVER.
  • SNOA's SEC filings can be seen here. And to visit SONOMA PHARMACEUTICALS INC's official web site, go to www.sonomapharma.com.

SNOA Valuation Summary

  • In comparison to the median Healthcare stock, SNOA's price/earnings ratio is 102.62% lower, now standing at -0.7.
  • SNOA's price/earnings ratio has moved up 3.4 over the prior 203 months.

Below are key valuation metrics over time for SNOA.

Stock Date P/S P/B P/E EV/EBIT
SNOA 2023-09-22 0.3 0.6 -0.7 -0.2
SNOA 2023-09-21 0.3 0.5 -0.7 -0.2
SNOA 2023-09-20 0.3 0.5 -0.7 -0.2
SNOA 2023-09-19 0.4 0.6 -0.8 -0.3
SNOA 2023-09-18 0.4 0.6 -0.8 -0.3
SNOA 2023-09-15 0.4 0.7 -0.9 -0.3

SNOA Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -72.64%.
  • Its 3 year net income to common stockholders growth rate is now at 56.89%.
  • Its year over year cash and equivalents growth rate is now at 75.26%.
SNOA's revenue has moved down $5,250,000 over the prior 52 months.

The table below shows SNOA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 12.556 -5.106 -6.787
2022-09-30 12.514 -5.084 -5.792
2022-06-30 12.927 -4.558 -4.875
2022-03-31 12.628 -4.248 -5.086
2021-12-31 12.487 -4.329 -5.802
2021-09-30 14.521 -3.257 -5.508

SNOA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SNOA has a Quality Grade of D, ranking ahead of 19.4% of graded US stocks.
  • SNOA's asset turnover comes in at 1.011 -- ranking 24th of 682 Pharmaceutical Products stocks.
  • AGLE, REGN, and NAVB are the stocks whose asset turnover ratios are most correlated with SNOA.

The table below shows SNOA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.011 0.348 -0.457
2021-03-31 1.064 0.352 -0.307
2020-12-31 1.210 0.393 -0.153
2020-09-30 1.226 0.405 -0.202
2020-06-30 1.214 0.411 -0.353
2020-06-30 1.305 0.416 -0.272

Sonoma Pharmaceuticals, Inc. (SNOA) Company Bio


Sonoma Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. Sonoma Pharmaceuticals serves customers worldwide.


SNOA Latest News Stream


Event/Time News Detail
Loading, please wait...

SNOA Latest Social Stream


Loading social stream, please wait...

View Full SNOA Social Stream

Latest SNOA News From Around the Web

Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has received the National Eczema

Yahoo | August 15, 2023

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2023.

Yahoo | August 10, 2023

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard

Yahoo | August 3, 2023

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2023 and the fourth quarter ended March 31, 2023.

Yahoo | June 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for a final look at the biggest pre-market stock movers this week as we check out what's happening on Friday morning!

William White on InvestorPlace | June 9, 2023

Read More 'SNOA' Stories Here

SNOA Price Returns

1-mo -16.30%
3-mo N/A
6-mo -18.35%
1-year -63.85%
3-year -90.78%
5-year -93.97%
YTD -31.25%
2022 -75.44%
2021 -37.19%
2020 66.51%
2019 -31.77%
2018 -86.97%

Continue Researching SNOA

Want to see what other sources are saying about Sonoma Pharmaceuticals Inc's financials and stock price? Try the links below:

Sonoma Pharmaceuticals Inc (SNOA) Stock Price | Nasdaq
Sonoma Pharmaceuticals Inc (SNOA) Stock Quote, History and News - Yahoo Finance
Sonoma Pharmaceuticals Inc (SNOA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!